These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 11362662)
21. A new approach to initial antiretroviral therapy: protease-sparing combination regimens. Hanna L BETA; 1998 Oct; ():9-13. PubMed ID: 11365999 [TBL] [Abstract][Full Text] [Related]
22. On the issue of cross-resistance between protease inhibitors. Birch C AIDS; 1998 Apr; 12(6):680-1. PubMed ID: 9583615 [No Abstract] [Full Text] [Related]
23. The choice of HIV protease inhibitor: indinavir is currently the best option. Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067 [TBL] [Abstract][Full Text] [Related]
25. Salvage therapy for patients failing their current antiretroviral regimen. Albrecht MA AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220 [No Abstract] [Full Text] [Related]
31. Developing long-term treatment strategies. PI Perspect; 1996 Sep; (No 19):11-4. PubMed ID: 11363897 [TBL] [Abstract][Full Text] [Related]
32. Saquinavir, the pioneer antiretroviral protease inhibitor. la Porte CJ Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1313-22. PubMed ID: 19737048 [TBL] [Abstract][Full Text] [Related]
33. [HIV infection. Compatibility of recent protease inhibitors in direct comparison - the advantage of DRV]. MMW Fortschr Med; 2014 Jun; 156 Suppl 1():52. PubMed ID: 25026859 [No Abstract] [Full Text] [Related]
35. Protease inhibitors in the homeless. Bangsberg D; Tulsky JP; Hecht FM; Moss AR JAMA; 1997 Jul; 278(1):63-5. PubMed ID: 9207341 [No Abstract] [Full Text] [Related]
36. HIV-protease inhibitors. Flexner C N Engl J Med; 1998 Apr; 338(18):1281-92. PubMed ID: 9562584 [No Abstract] [Full Text] [Related]
37. [Good experiences with saquinavir. Double boosting of protease inhibitors gains significance]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():44. PubMed ID: 15373047 [No Abstract] [Full Text] [Related]
38. Drug giant Bristol-Myers Squibb: Atazanavir moves into the spotlight while O83 bites the dust. Posit Aware; 2002; 13(4):42-3. PubMed ID: 12171044 [No Abstract] [Full Text] [Related]
39. Toxicity of antiretroviral therapy and implications for drug development. Carr A Nat Rev Drug Discov; 2003 Aug; 2(8):624-34. PubMed ID: 12904812 [No Abstract] [Full Text] [Related]